PeptidesInfo

Comparison

CJC-1295 vs ipamorelin vs tesamorelin

Three growth-hormone-axis peptides compared: one FDA-approved with phase 3 trials, two with only early human pharmacology and discontinued development programmes.

Updated

Bottom line

Tesamorelin is the only one of the three with an FDA approval and phase 3 outcome trials — for a narrow indication. CJC-1295 and ipamorelin raise GH and IGF-1 in short human studies but have no controlled trials of body composition, recovery or aging outcomes, and both were discontinued by their developers. Combining them does not create evidence that neither has alone.

Dimension
Tesamorelin
Established evidenceFDA-approved for this use
ClassGHRH analogue (with or without DAC)Ghrelin-receptor agonist (GHRP)GHRH analogue
Human evidenceSmall phase 1/2 pharmacology studies: raises GH/IGF-1 for days (DAC form)Phase 1 pharmacology; phase 2 post-operative ileus trial (discontinued, no efficacy)Two phase 3 RCTs (n≈800): reduces visceral fat in HIV-associated lipodystrophy
Outcome trialsNoneNone for any marketed useYes: visceral adipose tissue, phase 3
Evidence level (body composition)PreclinicalPreclinicalEstablished (HIV lipodystrophy only)
US regulatory statusNot FDA-approved; development discontinued; category 2 nomination withdrawn, still not compoundableNot FDA-approved; development discontinued; remains category 2 under the 503B policyFDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy abdominal fat
Known safety issuesHeadache, flushing, injection-site reactions; long-term GH/IGF-1 elevation unstudiedLimited data; short-term tolerability onlyInjection-site reactions, arthralgia, fluid retention, glucose intolerance; IGF-1 monitoring; contraindicated in active malignancy
Anti-doping statusProhibited (S2)Prohibited (S2)Prohibited (S2)

Same axis, very different evidence

All three act on the growth hormone axis — CJC-1295 and tesamorelin as GHRH analogues, ipamorelin as a ghrelin-receptor agonist — and all three raise growth hormone and IGF-1 in humans. That is where the similarity ends. Tesamorelin was carried through two phase 3 trials to an FDA approval; CJC-1295 and ipamorelin were dropped by their developers before any outcome trial was completed, and survive today as "research" products.

What tesamorelin's approval does and doesn't say

The approval is for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That population, that endpoint. Using tesamorelin for body composition in people without HIV, or for "anti-aging", is off-label, and the trials to support it are small or absent. It is also expensive and, per its label, needs IGF-1 monitoring.

The "CJC/ipa" stack

The combination is popular because GHRH analogues and GHRPs act synergistically on GH release in pharmacology studies. Synergy on a hormone level is not synergy on an outcome. There is no controlled trial of the combination for any clinical endpoint that we can find. The FDA placed both compounds in category 2 of its compounding interim policies in September 2023, citing possible immunogenicity. On the list current at 22 April 2026, ipamorelin acetate remains in category 2 under the 503B policy while the CJC-1295 nomination has been withdrawn — and neither is on the 503A bulks list, so neither can lawfully be compounded.

Go deeper

Research analysis5 min read

CJC-1295 and Ipamorelin: Growth Hormone Research and Unanswered Risks

The 'CJC/ipa' stack is sold for muscle, fat loss, sleep and anti-aging. The human evidence is a handful of short hormone-level studies, two abandoned development programmes, and no outcome trials — plus a set of risks that have never been studied because the trials were never run.

Research analysis4 min read

Tesamorelin: Approved Use, Off-Label Interest, and Clinical Evidence

Tesamorelin is the one GHRH analogue that finished phase 3 and won FDA approval — for excess abdominal fat in HIV-associated lipodystrophy. We separate that established evidence from the off-label uses it is now marketed for: general visceral fat, liver fat, and cognition.